ArticleJournal of medicinal chemistry2022
Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections.
Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Efficacy and Safety of Pritelivir vs Foscarnet for the Treatment of Acyclovir-Refractory Herpes Simplex Virus Infection in Immunocompromised Adults: A Randomized, Open-Label Phase 2 Trial.Open forum infectious diseases · 2026Trial
- A Modular Synthesis of C5-Sulfenyl Thiazoles via an Intermolecular Pummerer Rearrangement: An Underexplored Scaffold for Medicinal Chemistry.Angewandte Chemie (International ed. in English) · 2026Article
- Treatment of Herpes simplex encephalitis with the helicase-primase inhibitor pritelivir in an immunocompromised patient.npj antimicrobials and resistance · 2026Article
- Cell death network regulation in HSV infection: immune evasion versus host defense.Apoptosis : an international journal on programmed cell death · 2026Review
- Design, Synthesis of Pyridine Based Thiazolidine Derivatives and Investigation of Antimicrobial Activity Targeting Ergosterol Biosynthesis via In Vitro and In Silico Approaches.Chemical biology & drug design · 2026Article
- Refractory Mucocutaneous Infections by Herpes Simplex Virus (HSV) in Hematopoietic Cell Transplant Recipients: A Real-world, Multicenter Study.Open forum infectious diseases · 2026Article
- Article
- Mechanisms of HSV-1 helicase-primase inhibition and replication fork complex assembly.bioRxiv : the preprint server for biology · 2025Article
- Structural and mechanistic insights into the herpes simplex virus type 1 helicase-primase primosome.Cell discovery · 2025Article
- Structural basis of herpesvirus helicase-primase inhibition by pritelivir and amenamevir.Science advances · 2025Article
- Nanomaterial-Enhanced Electrochemical Sensors for Clinical Monitoring of Acyclovir: Integration Into Molecular Diagnostics.Journal of clinical laboratory analysis · 2025Review
- Identification of Direct-Acting nsP2 Helicase Inhibitors with Antialphaviral Activity.Journal of medicinal chemistry · 2025Article
- Bidirectional transfer of pritelivir across term human placenta and its effect on placental functions.The Journal of pharmacology and experimental therapeutics · 2025Article
- Structural Chemistry of Helicase Inhibition.Journal of medicinal chemistry · 2025Review
- The opportunities and challenges of epigenetic approaches to manage herpes simplex infections.Expert review of anti-infective therapy · 2024Review
- The immunobiology of corneal HSV-1 infection and herpetic stromal keratitis.Clinical microbiology reviews · 2024Review
- Emerging drugs for the treatment of herpetic keratitis.Expert opinion on emerging drugs · 2024Review
- A Multicenter Assessment of the Outcomes and Toxicities of Foscarnet for Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex in Immunocompromised Patients.Open forum infectious diseases · 2024Article
- Article
- Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers.Pharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When the nucleoside analogue acyclovir was introduced in the early 1980s, it presented a game-changing treatment modality for herpes simplex virus infections. Since then, work has been ongoing to improve the weaknesses that have now been identified: a narrow time window for therapeutic success, resistance in immunocompromised patients, little influence on frequency of recurrences, relatively fast elimination, and poor bioavailability. The present Drug Annotation focuses on the helicase-primase inhibitor pritelivir currently in development for the treatment of acyclovir-resistant HSV infections and describes how a change of the molecular target (from viral DNA polymerase to the HSV helicase-primase complex) afforded improvement of the shortcomings of nucleoside analogs. Details are presented for the discovery process leading to the final drug candidate, the pivotal preclinical studies on mechanism of action and efficacy, and on how ongoing clinical research has been able to translate preclinical promises into clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.